Sorin Petcu – General Manager, IQVIA Romania
Sorin Petcu of IQVIA Romania explains how financing, a lack of medical professionals, and an array of unmet needs are the major trends currently shaping Romanian healthcare. Petcu highlights IQVIA’s…
Address: Str. Polona, nr. 68 – 72, etaj 3, sector 1, Bucuresti 010505
Tel: +40 21-412.00.17
Web: http://www.egis.ro/
As EGIS Group, we are present with our products in more than 60 countries worldwide and the share of our export revenue in our total sales has been steadily growing, having reached 73% in the 2009/2010 financial year. Our extensive foreign market infrastructure is the guarantee for further growth and international success. Currently we have commercial offices and trading companies in 18 countries. In our strategic markets (Russia, other CIS-countries and Central Eastern Europe) sales is supported by a well-established marketing and distribution network, whereas in our Western and third world markets we work together with local partners.
EGIS Pharmaceuticals PLC is one of the leading pharmaceutical companies in Central Europe. Our most important activities are the production of pharmaceuticals and active pharmaceutical ingredients, pharmaceutical research and development, sales of finished products and active pharmaceutical ingredients.
Out of our three production facilities, two are in Budapest. One of them is seated in our headquarters, in Keresztúri Street, where Active Pharmaceutical Ingredients are made, and the other is in Bökényföldi Street, with our tablet, injection and packaging plants as well as commercial warehouses.
In our third facility, in Körmend, tablets, ointments, suppositories, solutions, syrups and aerosols are made and packaged.
Our production system meets the international GMP principles and the regulations of the Hungarian National Institute of Pharmacy.
Production of Active Pharmaceutical Ingredients
Production of active pharmaceutical ingredients is an important field in the activity of EGIS PLC (and its legal predecessors). As a result of professional experience accumulated through the efforts of the last decades and the continuous modernization of the facilities, competitiveness of the production of active pharmaceutical ingredients has been maintained as it is well proved by successful exports and the good results of the national and international official controls.
At present, in this field of activity approximately 50 different active pharmaceutical ingredients and their intermediates are produced a year. The wide scale of products can be characterized by the gradual renewal and replacement of individual products.
Production of active pharmaceutical ingredients has been able to respond to the challenges of quality assurance and environment protection of the recent past successfully. Thorough grounding and commitment of people working in this strategic field are an important part of the complex professional culture belonging to EGIS.
Pharmaceutical Research and Development
Our research activity is aimed at the development of generic pharmaceutical products offering high marketing potential, the chemical synthesis of putative original drug molecules, and testing of their pharmacological effects. Our research work focuses on drugs effective on cardiovascular diseases, disorders of the central nervous system, the respiratory and digestive systems. At the end of our business year, closed on 30th September 2010, the number of our registrations and marketing authorizations totalled up to 2400.
Sales of Finished Products and Active Pharmaceutical Ingredients
EGIS PLC is ranked third on the basis of the number of packages sold in the Hungarian market, and is placed fifth concerning our sales revenue.
73% of our sales revenue comes from our export activity. We export our finished products first of all to the Eastern regions like Russia, Central- and Eastern-European countries, and the CIS countries. As for the Western countries France and the UK are among our main markets for finished products, while France, the Netherlands, Japan and the United States are considered as the greatest markets for our active ingredients and intermediate export.
Sorin Petcu of IQVIA Romania explains how financing, a lack of medical professionals, and an array of unmet needs are the major trends currently shaping Romanian healthcare. Petcu highlights IQVIA’s…
Gabriel Cernica, general manager of Cegedim Customer Information and Cegedim Rx Romania, analyses the main trends shaping the pharmaceutical and healthcare environment in Romania and their effect on Cegedim’s business.…
Amalia Mihai, market access manager of Ipsen Romania explains that over the course of 26 years Ipsen has been increasingly helping Romanian patients in the field of oncology, neurodegenerative disorders,…
Daniel Bran, GM of Accord Romania reveals that finding the right talent has been one of the most challenging and rewarding milestones in building the affiliate from the ground up.…
Cătălin Vicol introduces Biofarm, a leading Romanian pharma producer on the verge of significant international expansion. Vicol shares his insights on the potential of the Romanian consumer healthcare (CHC) market,…
Jorge Levinson, head of Bayer Pharmaceuticals Romania and Moldova, reveals his first impressions of Romania and the untapped potential it offers to the company. He shares his insights on how…
Dana Constantinescu of GSK Romania reveals the importance of the affiliate to the regional group and how vaccines and HIV are driving its growth. She outlines how the affiliate’s portfolio…
Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a larger scale. He reveals how BMS has…
Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market…
Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the…
Jorge Ruiz Benecke of AbbVie Romania outlines how the affiliate attained its leading position in the Romanian pharma market, the importance of agility in the decision-making process, and how he…
Fotis Kalantzis, general manager for the Romanian affiliate of OTC medicine and food supplement specialist Perrigo reveals how the switch to a consumer-centric model was inducive to winning an IQVIA…
See our Cookie Privacy Policy Here